» Articles » PMID: 35887653

Transition in Sickle Cell Disease (SCD): A German Consensus Recommendation

Overview
Journal J Pers Med
Date 2022 Jul 27
PMID 35887653
Authors
Affiliations
Soon will be listed here.
Abstract

Sickle cell disease (SCD) is considered a rare disease in Germany. Due to the increasing prevalence, the acute and chronic morbidities associated with the disease and the sharp increase in the mortality rate of young adults, a need-based transition structure for patients with SCD in Germany is explicitly required. This is the first multicenter German consensus statement addressing the importance of implementing a standardized transition guideline that allows adolescents and young adults to safely transition from pediatric to adult care. Early identification of medical needs and intervention remains important in the context of chronic diseases. Effective measures can improve health care in general, as they lead to a reduction in disease and the consequential economic burden. It is noteworthy that improving structural barriers remains a key challenge even in highly developed countries such as Germany. Inclusion of these transition services for patients with SCD into the regular care of chronically ill adolescents and young adults should be ensured, as well as the coverage of costs associated with a structured transition process.

Citing Articles

Current Status of Newborn Bloodspot Screening Worldwide 2024: A Comprehensive Review of Recent Activities (2020-2023).

Therrell B, Padilla C, Borrajo G, Khneisser I, Schielen P, Knight-Madden J Int J Neonatal Screen. 2024; 10(2).

PMID: 38920845 PMC: 11203842. DOI: 10.3390/ijns10020038.


Patient, caregiver and other knowledge user engagement in consensus-building healthcare initiatives: a scoping review protocol.

Munce S, Wong E, Luong D, Rao J, Cunningham J, Bailey K BMJ Open. 2024; 14(5):e080822.

PMID: 38719333 PMC: 11086512. DOI: 10.1136/bmjopen-2023-080822.


Special Issue "Personalized Medicine in Blood Disease of Children".

Ceci A, Kountouris P, Didio A, Bonifazi F J Pers Med. 2024; 14(3).

PMID: 38541027 PMC: 10971618. DOI: 10.3390/jpm14030285.

References
1.
Shafrin J, Thom H, Keeney E, Gaunt D, Zhao L, Bhor M . The impact of vaso-occlusive crises and disease severity on quality of life and productivity among patients with sickle cell disease in the US. Curr Med Res Opin. 2021; 37(5):761-768. DOI: 10.1080/03007995.2021.1897556. View

2.
Lobitz S, Telfer P, Cela E, Allaf B, Angastiniotis M, Johansson C . Newborn screening for sickle cell disease in Europe: recommendations from a Pan-European Consensus Conference. Br J Haematol. 2018; 183(4):648-660. DOI: 10.1111/bjh.15600. View

3.
Kunz J, Schlotmann A, Daubenbuchel A, Lobitz S, Jarisch A, Grosse R . Benefits of a Disease Management Program for Sickle Cell Disease in Germany 2011-2019: The Increased Use of Hydroxyurea Correlates with a Reduced Frequency of Acute Chest Syndrome. J Clin Med. 2021; 10(19). PMC: 8509263. DOI: 10.3390/jcm10194543. View

4.
Piel F, Steinberg M, Rees D . Sickle Cell Disease. N Engl J Med. 2017; 376(16):1561-1573. DOI: 10.1056/NEJMra1510865. View

5.
Blum R, GARELL D, HODGMAN C, Jorissen T, Okinow N, Orr D . Transition from child-centered to adult health-care systems for adolescents with chronic conditions. A position paper of the Society for Adolescent Medicine. J Adolesc Health. 1993; 14(7):570-6. DOI: 10.1016/1054-139x(93)90143-d. View